ConductScience.org, home

Comparison · NCT01193257-2afaee9d

Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Placebo + Prednisone vs Orteronel + Prednisone: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs). Trial comparisons, record NCT01193257-2afaee9d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01193257-2afaee9d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.950.9230.968wilson
Risk in group 20.9820.970.99wilson
Risk difference, group 1 minus group 2-0.0318-0.0602-0.00998newcombe hybrid score
Risk ratio, group 1 over group 20.9680.9430.993log
Odds ratio, group 1 over group 20.3470.1680.715log
Number needed to treat, for one fewer participant with the outcome on Placebo + Prednisone than on Orteronel + Prednisone31.416.6100from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Placebo + PrednisoneOrteronel placebo-matching tablets, orally, twice daily (BID) and prednisone 5 mg, tablets, orally, BID up to Day 28 of each treatment cycle throughout the study.345363OG000
Group 2Orteronel + Prednisone
Orteronel 400 mg, tablets, orally, BID and prednisone 5 mg, tablets, orally, BID up to Day 28 of each treatment cycle throughout the study. In Japan only, participants were administered with orteronel 300 mg, tablets, orally, BID and prednisone 5 mg, tablets, orally, BID up to Day 28 of each treatment cycle throughout the study.
719732OG001

Outcome

Type
SECONDARY
Title
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Description
Time frame
Baseline up to 30 days after last dose of study drug (Cycle 59 Day 58)
Population
Safety population included all participants who received at least 1 dose of any study drug.

Source ClinicalTrials.gov

Trial

Title
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
NCT number
NCT01193257
Phases
PHASE3
Conditions
Prostate Cancer
Interventions
Orteronel, Prednisone, Orteronel Placebo
Lead sponsor
Millennium Pharmaceuticals, Inc.
Results first posted
2018-12-19

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01193257-2afaee9d